Reference | Year | No. of patients | A/P RAMPS | Tumor size (cm) | N+(%) | R0(%) | Lymph Node harvested | Median follow-up time(months) | Recurrence rate (%) | Median survival time (months) | 5-year overall survival (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
Strasberg [19] | 2003 | 10 | 6/4 | 4(2–15) | NA | 90 | 1–28 | NA | 3(30.0%) | NA | NA |
Strasberg [32] | 2007 | 23 | 15/8 | 5.1 ± 2.6 | 48 | 87 | 14.3 ± 7.8 | 17 for alive | 11(47.8%) | NA | NA |
Kanga [41] | 2010 | 5 | 5/0 | 2.4 ± 0.7 | 20 | 100 | 8.2 ± 5.9 | 13(4–21) | 1(20%) | NA | NA |
Ikegami [42] | 2011 | 6 | 3/3 | 3.0 ± 0.9 | NA | 100 | NA | NA | NA | NA | NA |
Mitchem [43] | 2012 | 47 | 32/15 | 4.4 ± 2.1 | 55 | 80.1 | 18.0 ± 11.7 | 26.4 for alive | 27(57.4%) | 25.9 | 35.5 |
Chang [44] | 2012 | 24 | 19/5 | 4.09 ± 2.15 | 70.8 | 91.7 | 20.92 ± 11.24 | 20.06 | 21(87.5%) | 18.2 | NA |
Kim [45] | 2013 | 12 | 12/0 | 2(0.8–4.0) | 50 | NA | 17(5–29) | NA | NA | NA | NA |
Rosso [46] | 2013 | 10 | 1/9 | 4.65(1.0–8.0) | 70 | 90 | 17(13–95) | 19.1 ± 10.1 | NA | 20.5% | NA |
Leeb [39] | 2014 | 12 | 12/0 | 2.75 ± 1.32 | 25 | 100 | 10.5 ± 7.14 | 39 | 5(41.7%) | 60.0 | 55.6 |
Kitagawac [38] | 2014 | 24 | 19/5 | 3.5 ± 1.4 | 54.2 | 88 | 28 ± 12 | 52 for alive | 10(41.7%) | NA | 53 |
Kawabatad [37] | 2015 | 11 | NA | 3.35(1.9–5.5) | 91 | 77 | 26(9–80) | 12.4(3.5–16.4) | 1(9.1%) | NA | NA |
Murakawa [12] | 2015 | 49 | NA | 0.5–8.3 | 55 | 83.7 | 15 | 41.4 | 30(61.2%) | 22.6 | 27 |
Grossman [31] | 2016 | 78 | 56/22 | 4.71 | 47 | 85 | 20 ± 12.2 | 20.6 (0.3–145.3) | 49(62.8%) | 24.6 | 25.1 |